ACRX AcelRx Pharmaceuticals Inc.

2.78
-0.09  -3%
Previous Close 2.87
Open 2.83
Price To Book -4.56
Market Cap 172102216
Shares 61,907,272
Volume 1,640,430
Short Ratio
Av. Daily Volume 4,783,634

NewsSee all news

  1. 3 Stocks to Hold for the Next 20 Years
  2. AcelRx Pharmaceuticals to Host Analyst and Investor Day on December 11
  3. New Healthcare Trends Could Push Sector Stocks Higher
  4. Edited Transcript of ACRX earnings conference call or presentation 5-Nov-18 1:30pm GMT
  5. AcelRx Pharmaceuticals to Present at the 17th Annual ASRA Pain Medicine Meeting

SEC filingsSee all SEC filings

  1. 8-K - Current report 181179155
  2. 424B5 - Prospectus [Rule 424(b)(5)] 181179103
  3. 424B5 - Prospectus [Rule 424(b)(5)] 181171317
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181158971
  5. 8-K - Current report 181157171

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released August 15 2016
ARX-04 (SAP302)
Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury
FDA Approval announced November 2, 2018.
DSUVIA (ARX-04)
Moderate-to-severe acute pain following a surgical procedure
CRL Jul 26 2014. NDA resubmission timing being evaluated.
Zalviso
Post-operative pain following open abdominal surgery and hip or knee replacement surgery

Latest News

  1. 3 Stocks to Hold for the Next 20 Years
  2. AcelRx Pharmaceuticals to Host Analyst and Investor Day on December 11
  3. New Healthcare Trends Could Push Sector Stocks Higher
  4. Edited Transcript of ACRX earnings conference call or presentation 5-Nov-18 1:30pm GMT
  5. AcelRx Pharmaceuticals to Present at the 17th Annual ASRA Pain Medicine Meeting
  6. Here's Why AcelRx Pharmaceuticals Lost as Much as 18.4% Today
  7. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  8. Report: Exploring Fundamental Drivers Behind AcelRx Pharmaceuticals, Fossil Group, FMC, Ultragenyx Pharmaceutical, Shenandoah Telecommunications, and Marcus & Millichap — New Horizons, Emerging Trends, and Upcoming Developments
  9. AcelRx Pharmaceuticals Announces Proposed Public Offering of Common Stock
  10. AcelRx Pharmaceuticals to Present at Credit Suisse 27th Annual Healthcare Conference
  11. Powerful new opioid 500 times stronger than morphine approved in U.S. in spite of outcry
  12. Health Care Digest: Health's push onto the ballot, an exec's cancer story and more
  13. Why AcelRx Pharmaceuticals Stock Is Slipping Today
  14. Monday's Top Healthcare Stocks To Watch Ahead Of Elections
  15. Today’s Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and Sage Therapeutics
  16. 3 Big Stock Charts for Monday: Coca-Cola, Kinder Morgan and Adobe
  17. Noting Military Potential, FDA Approves Powerful Painkiller Dsuvia
  18. AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates
  19. AcelRx Pharmaceuticals: 3Q Earnings Snapshot
  20. AcelRx Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

SEC Filings

  1. 8-K - Current report 181179155
  2. 424B5 - Prospectus [Rule 424(b)(5)] 181179103
  3. 424B5 - Prospectus [Rule 424(b)(5)] 181171317
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181158971
  5. 8-K - Current report 181157171
  6. 8-K - Current report 181156718
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 18989533
  8. 8-K - Current report 18988240
  9. 8-K - Current report 18952560
  10. 424B5 - Prospectus [Rule 424(b)(5)] 18952551